Drug Delivery System
Online ISSN : 1881-2732
Print ISSN : 0913-5006
ISSN-L : 0913-5006
Search
Advanced search
OR
Browse
Search
Volume 19, Issue 4
Displaying 1-8 of 8 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
  • Hope for RNAi and Pharmaceutical companies?
    Kazunari Taira
    2004 Volume 19 Issue 4 Pages 343
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.343
    JOURNAL FREE ACCESS
    Download PDF (257K)
  • Prospects for RNA medicines in post-genomic drug discovery
    Junichi Yano
    2004 Volume 19 Issue 4 Pages 345
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.345
    JOURNAL FREE ACCESS
    Download PDF (198K)
  • RNAi and siRNA
    Molecular design of siRNA
    Koichi Yoshinari, Makoto Miyagishi, Kazunari Taira
    2004 Volume 19 Issue 4 Pages 348-355
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.348
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Selection of target sites is one of key issues in knock-down experiments using siRNA. So far, our systematic analysis of siRNA effects at various target sites revealed that siRNA activities are dependent on some nucleotides at specific position of target sequences and tight secondary structure of target messages, but are independent of the position in the target message. Here we review recent findings concerning mechanism of RNAi and factors that affect siRNA activities, and provide a basis for designing siRNA and siRNA expression vector.
    View full abstract
    Download PDF (1883K)
  • RNAi and siRNA
    Development of delivery system for siRNA using atelocollagen as a carrier material
    Yoshiko Minakuchi, Fumitaka Takeshita, Shunji Nagahara, Takahiro Ochiy ...
    2004 Volume 19 Issue 4 Pages 356-363
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.356
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Silencing of gene expression by siRNA is one of the powerful tool for genetic analysis in vitro and in vivo. siRNA technique is simple and its effect is sharp rather than antisense DNA, so many feasibility studies for its therapeutic use have been conducted. However, the utility of siRNA for therapeutic application is hampered by absence reliable and safe delivery method. Recently, we have established atelocollagen-mediated delivery system for therapeutic use of nucleic acid medicines such as plasmid DNA and antisense DNA. In this article, application of siRNA to our delivery system and its effectiveness in animals was described.
    View full abstract
    Download PDF (1810K)
  • RNAi and siRNA
    A development of the efficient siRNA-expression vector by the use of peptide-DNA conjugate
    Yutaka Ikeda, Kazunari Taira
    2004 Volume 19 Issue 4 Pages 364-372
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.364
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    RNA interference (RNAi) is a natural phenomenon whereby double-stranded RNA induces the sequence-dependent degradation of a cognate mRNA in cells. The potential application to the treatment of inherited genetic diseases is considerable and has led to attempts of RNAi to develop type of gene therapy. Such therapy will only be possible if suitable expression vectors can be generated. The chemical modification of DNA might help to solve some of the problems associated with non-viral vectors. DNA can be modified with various bioactive molecules including cholesterol, sugar, peptide and even protein. These molecules are versatile enough to impart virtually any desired biological property, and have been used as enhancers of certain properties in DNA. In this review, we will focus on recent progresses of the synthesis and applications of DNA conjugate.
    View full abstract
    Download PDF (2054K)
  • RNAi and siRNA
    Development of supramolecular nanocarrier of siRNA
    Keiji Itaka, Kazunori Kataoka
    2004 Volume 19 Issue 4 Pages 373-378
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.373
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    For n vivo therapeutic applications of RNAi, the siRNA delivery systems should possess highly-developed functions such as the controllable onset and duration of gene knockdown at the targeted cells. For this purpose, we developed siRNA nanocarriers formed through the multimolecular assembly of block copolymers. In this review article, the structural design of the carriers, the physicochemical properties, and the gene knockdown abilities are described.
    View full abstract
    Download PDF (1323K)
  • RNAi and siRNA
    Delivery of siRNA using HVJ envelope vector
    Yasufumi Kaneda
    2004 Volume 19 Issue 4 Pages 379-384
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.379
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We have been developing HVJ (hemagglutinating virus of Japan)-liposomes for the delivery of genes and drugs. Recently, we succeeded in incorporating DNA and drugs into inactivated HVJ particle without liposomes. The resulting HVJ envelope vector can fuse with cell membrane to directly introduce genes and drugs into cells. The vector is found to be very effective for the delivery of siRNA both in cultured cells and in various tissues. This system will be very useful for the analysis of gene functions and for the treatment of intractable human diseases.
    View full abstract
    Download PDF (1376K)
  • RNAi and siRNA
    RNAi-based gene silencing in mice
    Makiya Nishikawa, Naoki Kobayashi, Yoshinobu Takakura
    2004 Volume 19 Issue 4 Pages 385-391
    Published: July 10, 2004
    Released on J-STAGE: December 09, 2008
    DOIhttps://doi.org/10.2745/dds.19.385
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    RNA interference(RNAi) is expected to be a novel therapeutic method for various diseases including cancer, AIDS and viral hepatitis. RNAi-based therapy could be realized by the development of efficient delivery system for small interfering RNA(siRNA), the effector molecule in RNAi. Because various methods are available to deliver siRNA into the cytoplasm of cultured cells, such as viruses, transfection reagents, and electroporation, RNAi-based knock down is becoming a standard to identify the function of the gene of interest. However, the application of siRNA or siRNA-expressing vector to in vivo gene silencing for the treatment of diseases has encountered with barriers on the delivery. To overcome these problems, the development of delivery system is highly required. Delivery methods that have been developed for in vivo delivery of antisense oligonucleotides and genes can be applied to siRNA or siRNA-expressing vectors, Recently, we have shown that siRNA and siRNA-expressing plasmid DNA efficiently delivered to the liver can significantly suppress target genes. In this review, we summarize the possibility of in vivo RNAi by delivering siRNA or siRNA-expressing vectors in mice.
    View full abstract
    Download PDF (1731K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top